Clinical Trials Logo

Severe Eosinophilic Asthma clinical trials

View clinical trials related to Severe Eosinophilic Asthma.

Filter by:

NCT ID: NCT04084613 Active, not recruiting - Clinical trials for Severe Eosinophilic Asthma

Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece

Start date: January 2017
Phase:
Study type: Observational

A prospective multi-centre, non-interventional observational study, that will be conducted in several centers in Greece for a 2-year time period (completion date December 2020), to describe patient characteristics, medical history, and the clinical benefit of mepolizumab in patients with severe eosinophilic asthma newly initiated to the drug.

NCT ID: NCT03907137 Completed - Clinical trials for Severe Eosinophilic Asthma

Real World Study With Benralizumab in Severe Asthma in Switzerland

BEEPS
Start date: January 21, 2019
Phase:
Study type: Observational

BEEPS describes the utility of patient reported outcomes (PRO) as simple, pragmatic, and sensitive tool to assess early treatment response of benralizumab to document the level of asthma control and change in medication after 1 to 16 weeks post-treatment initiation including use of OCS. The generated data on the time of asthma symptom relief after initiation of benralizumab will support patient management for a better disease control in severe asthma patients under benralizumab treatment. To assess long term outcomes the patients will have a last mandatory visit after 56 weeks, with no visits scheduled between week 16 and 56.

NCT ID: NCT03833141 Active, not recruiting - Clinical trials for Severe Eosinophilic Asthma

Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.

POWER
Start date: November 12, 2018
Phase:
Study type: Observational

This study will generate patient reported outcomes (PROs) associated with the use of benralizumab as treatment for severe eosinophilic asthma.

NCT ID: NCT03739320 Recruiting - Clinical trials for Severe Eosinophilic Asthma

A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma

Start date: December 11, 2017
Phase:
Study type: Observational

Daily physical activity in adult patients with asthma remains overlooked. Limited evidence demonstrates reduced levels of daily physical activity in asthma populations but studies examining the potential effect of available therapies are missing. This study aims to investigate the overall levels of daily physical activity in patients with severe eosinophilic asthma and whether anti-interleukin-5 therapy with mepolizumab, on top of existing, maximal, and optimised asthma treatment, may improve patient's daily physical activity.

NCT ID: NCT03652376 Not yet recruiting - Clinical trials for Severe Eosinophilic Asthma

Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma

Start date: September 1, 2018
Phase: Phase 4
Study type: Interventional

This study investigates the effect of removing eosinophils from peripheral blood (using treatment with Benralizumab, which is approved for the treatment of severe eosoniphilic asthma) on circulating dendritic cells in patients with severe eosinophilic asthma.

NCT ID: NCT02560610 Completed - Clinical trials for Severe Eosinophilic Asthma

Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma

Start date: September 2016
Phase: Phase 2
Study type: Interventional

The aim is to study the effect of OC000459 on eosinophilic airway inflammation and asthma control in subjects with severe, refractory eosinophilic asthma.